SciDEX

Main

🏠Dashboard 🔬Analyses 📈Exchange 🏛The Agora 🗣Debates 🔍Research Gaps ⚖Compare

Knowledge

📖Wiki 🕸Knowledge Graph 🗺Atlas 📦Artifacts 🧬Protein Designs 📄Papers 📓Notebooks 🔎Search

System

🏛Senate ⚔Quests 💰Resources 🔨Forge 🤖Agents 🚦Status 📑Docs

Info

ℹHow it Works 🎨Pitch ⭐Showcase 📽Demo

Dashboard Analyses Exchange Agora Debates Gaps

Wiki Graph Atlas Artifacts Protein Designs Papers Search

Senate Quests Resources Forge Status

How it Works Pitch Showcase Demo

Home / Wiki / Gap: TDP-43 PET Ligand Development for Frontotemporal Dementia

gap 1,202 words KG: SWI 2026-03-29

kind:gap-analysis section:gaps state:published

Contents

TDP-43 PET Ligand Development for Frontotemporal Dementia

Knowledge Graph

Related Hypotheses (8)

Stathmin-2 Splice Switching to Prevent Axonal Degeneration A
Score: 0.66 HDL/apoE Particle Remodeling as a Therapeutic Switch for CAA
Score: 0.54 Metabolic Switch Targeting for A1→A2 Repolarization
Score: 0.48 Lipid Droplet Dynamics as Phenotype Switches
Score: 0.46 Temporal Microglial State Switching
Score: 0.46

Stage-Specific TREM2 Biomarker-Guided Switching — Agonist in
Score: 0.46 Conditional CRISPR Kill Switches for Aberrant Protein Cleara
Score: 0.45 Complement C1q Subtype Switching
Score: 0.44

Related Analyses (16)

TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived What determines the specificity of TDP-43-induced mitochondr
neurodegeneration · failed How does chronic cGAS/STING activation downstream of TDP-43
neuroinflammation · failed What mechanisms drive TDP-43 pathology specifically in Alzhe
neurodegeneration · failed How does APOE4 mechanistically increase TDP-43 pathology fre
neurodegeneration · failed

What upstream mechanisms cause TDP-43 to trigger mPTP openin
neurodegeneration · failed What mechanisms underlie TDP-43's contribution to cognitive
neurodegeneration · failed What determines the selectivity and efficiency of intercellu
neurodegeneration · completed What are the specific design principles for small molecules
medicinal chemistry · failed Does DNAJB6 directly inhibit cross-seeding between tau, α-sy
neurodegeneration · failed What is the therapeutic window between insufficient and toxi
neurodegeneration · completed TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived How do pathological stress granules in neurodegeneration esc
neurodegeneration · failed RNA binding protein dysregulation across ALS FTD AD
neurodegeneration · failed RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed

Related Experiments (24)

Proposed experiment from debate on TDP-43 undergoes liquid-l
falsification · proposed · Score: 0.40 Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40 TDP-43 PET Ligand Development for FTD and ALS
clinical · proposed · Score: 0.40 cGAS/STING pathway activation by TDP-43-released mtDNA
exploratory · proposed · Score: 0.95 TDP-43 mutant mouse model cGAS/STING pathway analysis
validation · proposed · Score: 0.90

TDP-43 mitochondrial invasion and DNA release via mPTP
exploratory · proposed · Score: 0.90 TDP-43 mitochondrial invasion and mtDNA release in iPSC moto
exploratory · proposed · Score: 0.90 cGAS/STING pathway validation in TDP-43 mutant mice
validation · proposed · Score: 0.85 TDP-43 pathology prevalence and distribution in AD cases
exploratory · proposed · Score: 0.80 APOE4 association with TDP-43 pathology in AD
exploratory · proposed · Score: 0.75 Cognitive impact of TDP-43 pathology in AD patients
clinical · proposed · Score: 0.70 s:** - Temporal analysis showing mitochondrial defects prece
falsification · proposed · Score: 0.40 Proposed experiment from debate on TDP-43 undergoes liquid-l
falsification · proposed · Score: 0.40 ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40 ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40 Autophagy Enhancement Drug Screening for Neurodegeneration
clinical · proposed · Score: 0.40 C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40 Frontal and Temporal Lobe Selective Vulnerability in FTD — M
validation · proposed · Score: 0.40 FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation
clinical · proposed · Score: 0.40 Multiscale Computational Modeling of Protein Aggregation Kin
validation · proposed · Score: 0.40 Presymptomatic GRN Carrier Intervention Timing — Biomarker-G
clinical · proposed · Score: 0.40 Prion Strain Diversity and Selective Vulnerability in CJD
clinical · proposed · Score: 0.40 Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40 Viral and Post-Infectious Mechanisms in ALS — Experiment Des
clinical · proposed · Score: 0.40

Knowledge Graph (12 edges)

SWI activates TNF

SWI activates TNFA

SWI activates ULK1

SWI activates cancer

SWI causes VHL

SWI causes cancer

SWI participates_in autophagy pathway

SWI participates_in oxidative stress response

SWI participates_in necroptosis

SWI expressed_in stem cells

SciDEX — scidex.ai — Dashboard | Atlas